Company AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London Stock Exchange 11:35:02 2023-12-05 am EST Intraday chart for AstraZeneca PLC 5-day change 1st Jan Change
10,144 GBX -1.19% +2.46% -9.57%

Business Summary

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (3.1%).

Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).

Number of employees : 83,500

Sales per Business

GBP in Million2021Weight2022Weight Delta
Oncology
33.0 %
9,487 34.9 % 11,878 33.0 % +25.20%
Cardiovascular, Renal and Metabolism
20.7 %
5,831 21.4 % 7,459 20.7 % +27.91%
Rare Disease
15.9 %
2,232 8.2 % 5,726 15.9 % +156.51%
Respiratory and Immunology
13.0 %
4,387 16.1 % 4,680 13.0 % +6.67%
Vaccines and Immune Therapies
10.7 %
- - 3,845 10.7 % -
Other Medicines
3.7 %
1,721 6.3 % 1,319 3.7 % -23.35%
Collaboration
3.1 %
637 2.3 % 1,098 3.1 % +72.45%

Sales per region

GBP in Million2021Weight2022Weight Delta
United States
39.0 %
8,760 32.2 % 14,027 39.0 % +60.13%
China
12.9 %
4,364 16.0 % 4,662 12.9 % +6.83%
Japan
9.0 %
2,469 9.1 % 3,236 9.0 % +31.09%
United Kingdom
7.0 %
2,359 8.7 % 2,530 7.0 % +7.25%
Other Rest of Europe
6.1 %
1,417 5.2 % 2,197 6.1 % +55.02%
Other Asia, Africa and Australasia
5.4 %
1,730 6.4 % 1,953 5.4 % +12.92%
Germany
4.3 %
1,080 4.0 % 1,544 4.3 % +42.91%
Sweden
3.9 %
1,688 6.2 % 1,397 3.9 % -17.25%
Other Americas
2.6 %
875 3.2 % 954 2.6 % +9.05%
Canada
2.6 %
561 2.1 % 947 2.6 % +68.63%
France
2.5 %
665 2.4 % 899 2.5 % +35.08%
Spain
1.7 %
420 1.5 % 599 1.7 % +42.56%
Italy
1.7 %
420 1.5 % 597 1.7 % +42.23%
Australia
1.3 %
398 1.5 % 464 1.3 % +16.55%

Managers

Managers TitleAgeSince
Chief Executive Officer 63 2012
Director of Finance/CFO 49 2021
Chief Operating Officer 52 2015
Compliance Officer - 1997
Compliance Officer - 1994
Chief Tech/Sci/R&D Officer 59 -
Corporate Officer/Principal 63 -
Treasurer 58 -
Corporate Officer/Principal - 2017
Corporate Officer/Principal 50 2013

Members of the board

Members of the board TitleAgeSince
Director/Board Member 64 2017
Corporate Officer/Principal 58 2013
Director/Board Member 62 2017
Director/Board Member 67 1999
Corporate Officer/Principal 71 2013
Director/Board Member 66 2021
Chairman 67 2019
Chief Executive Officer 63 2012
Director/Board Member 63 2017
Director of Finance/CFO 49 2021

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,549,926,211 1,495,104,073 ( 96.46 %) 0 96.46 %

Shareholders

NameEquities%Valuation
Capital Research & Management Co. (World Investors)
5.502 %
85,277,128 5.502 % 10 607 M p
Wellington Management Co. LLP
4.085 %
63,310,758 4.085 % 7 875 M p
Investor AB (Investment Company)
3.328 %
51,587,810 3.328 % 6 416 M p
The Vanguard Group, Inc.
3.204 %
49,652,874 3.204 % 6 176 M p
Norges Bank Investment Management
2.342 %
36,299,481 2.342 % 4 515 M p
BlackRock Investment Management (UK) Ltd.
2.179 %
33,776,031 2.179 % 4 201 M p
Fidelity Management & Research Co. LLC
1.903 %
29,496,481 1.903 % 3 669 M p
T. Rowe Price Associates, Inc. (Investment Management)
1.879 %
29,128,975 1.879 % 3 623 M p
Capital Research & Management Co. (Global Investors)
1.746 %
27,057,449 1.746 % 3 365 M p
BlackRock Fund Advisors
1.358 %
21,051,933 1.358 % 2 618 M p
NameEquities%Valuation
Da Cheng Fund Management Co., Ltd.
0.001322 %
10,246 0.001322 % 794 762 p
NameEquities%Valuation
PRIMECAP Management Co.
1.301 %
40,337,578 1.301 % 2 551 M p
Sanders Capital LLC
0.3407 %
10,561,101 0.3407 % 668 M p
Managed Account Advisors LLC
0.2016 %
6,248,659 0.2016 % 395 M p
Farallon Capital Management LLC
0.1955 %
6,059,553 0.1955 % 383 M p
Merrill Lynch, Pierce, Fenner & Smith, Inc.
0.0998 %
3,092,655 0.0998 % 196 M p
Ensign Peak Advisors, Inc.
0.0834 %
2,584,673 0.0834 % 163 M p
Holocene Advisors, LP
0.0799 %
2,475,611 0.0799 % 157 M p
Morgan Stanley & Co. International Plc
0.0770 %
2,387,740 0.0770 % 151 M p
Wells Fargo Clearing Services LLC
0.0679 %
2,104,600 0.0679 % 133 M p
Renaissance Technologies LLC
0.0563 %
1,743,677 0.0563 % 110 M p

Holdings

NameEquities%Valuation
18,750,000 75.00% 1,052,603,250 $
16,000,000 28.79% 15,220,800 $
71,059,999 16.90% 56,823,839 $
7,485,500 9.28% 17,960,634 $
32,100,518 9.07% 659,096,824 $
4,011,215 4.97% 2,807,851 $
3,584,230 3.63% 849,463 $
884,956 2.20% 83,186 $

Company contact information

AstraZeneca PLC

2 Kingdom Street Paddington

W2 6BD, London

+44 20 3749 5000

http://www.astrazeneca.co.uk
address AstraZeneca PLC(AZN)

Group companies

NameCategory and Sector
AstraZeneca AB
Commercial Services - Miscellaneous Commercial Services
Health Technology - Pharmaceuticals: Major
AstraZeneca UK Ltd.
Health Technology - Pharmaceuticals: Major
R&Q Beta Co. Plc
Finance - Insurance Brokers/Services
AstraZeneca India Pvt Ltd.
Health Technology - Pharmaceuticals: Major
Astrazeneca Holdings BV
-
AstraZeneca Share Trust Ltd.
Commercial Services - Miscellaneous Commercial Services
AstraZeneca Employee Share Trust Ltd.
Commercial Services - Miscellaneous Commercial Services
Astrazeneca Treasury BV
-

Sales per Business

Sales per region

Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
127.81USD
Average target price
165.33USD
Spread / Average Target
+29.36%
Consensus
1st Jan change Capi.
-9.57% 198 B $
+60.77% 529 B $
+46.50% 444 B $
-10.25% 382 B $
-4.25% 269 B $
-10.54% 255 B $
-13.61% 231 B $
+1.76% 200 B $
-43.23% 164 B $
+3.13% 145 B $
Other Pharmaceuticals
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer